|
Mercado cerrado -
Nasdaq
22:00:00 13/02/2026
|
Variación 5 días
|
Varia. 1 de enero.
|
|
43,92 USD
|
+2,86 %
|
 |
+0,05 %
|
+0,21 %
|
|
11/02 |
Biogen Inc. Announces Board Changes
| | |
10/02 |
Exelixis : 260210 Exelixis Q4 & FY25 Earnings Presentation With Appendix
| | |
10/02 |
Exelixis : Annual Report for Fiscal Year Ending January 2, 2025 (Form 10-K)
| | |
10/02 |
(EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B - $2.63B, vs. FactSet Est of $2.62B
| | |
10/02 |
Exelixis: Q4 Earnings Snapshot
| | |
10/02 |
Earnings Flash (EXEL) Exelixis, Inc. Reports Q4 Revenue $598.7M, vs. FactSet Est of $596.5M
| | |
10/02 |
Earnings Flash (EXEL) Exelixis, Inc. Posts Q4 Adjusted EPS $0.94 per Share, vs. FactSet Est of $0.83
| | |
02/02 |
Sector Update: Health Care Stocks Higher Late Afternoon
| | |
02/02 |
Sector Update: Health Care Stocks Higher Monday Afternoon
| | |
02/02 |
Sector Update: Health Care
| | |
12/01 |
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on November 4, 2025.
| | |
12/01 |
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on February 20, 2025.
| | |
11/01 |
Exelixis : Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
| | |
11/01 |
Exelixis, Inc. Announces Preliminary Financial Results for the Year 2025 and Provides Financial Guidance for the Year 2026
| | |
11/01 |
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
| | |
08/01 |
Sector Update: Health Care
| | |
08/01 |
Exelixis Shares Fall After Downgrade From Morgan Stanley
| | |
07/01 |
Enliven Therapeutics, Inc. Announces Changes in Board, Effective January 7, 2026
| | |
07/01 |
Exelixis, Natera to Collaborate on Phase 3 Colorectal Cancer Trial
| | |
07/01 |
Exelixis and Natera to collaborate on Stellar-316, a phase 3 pivotal trial of zanzalintinib
| | |
07/01 |
Exelixis, Inc. and Natera Announce to Collaborate on STELLAR-316, Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
| | |
07/01 |
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
| | |
06/01 |
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
| | |
05/01 |
Exelixis Faces Limited High-Impact Catalysts, BofA Says
| | |
31/12 |
Exelixis, Inc.'s Equity Buyback announced on February 20, 2025, has closed with 12,271,791 shares, representing 4.5% for $500 million.
| |
No hay resultados para esta búsqueda Selecciona tu edición Toda la información financiera adaptada al ámbito nacional.
MarketScreener is also available in this country: United States.
Switch edition
Seguir con la edición actual
| 
